They just take a shotgun approach hoping for easy money.. Too many lawyers looking for any income.
Whether or not a product is ever made, the purpose of a patent was that no one could use an invention without the owner of a patent from being compensated. Many patent holders have never had a product go to market, yet they should enjoy protection.
Not until they pay down the billion they owe. Besides, they make more money running the old ones.
boby, I think cheerleading this stock and calling it a opportunity is irresponsible. The risks in both directions make this a large gamble, and not an investment.
No new auditing has taken place. We may not have a clear picture of what is going on until after the 2014 results are available. See what caveats E&Y adds in order to sign off on VNETs numbers. I guess I should say, if they sign off. E&Y record of being involved in scandals is not something they are going to want to add to.
Agree with bobo that any internal audits will be meaningless, as are analysts comments, company denials, etc.
Taser fell 3.5% and it wasnt nearly as hyped last few days. Everyone jumps on the bandwagon without doing the math. Small pies, with multiple players.
There is a reason the dividend is so high and its not because its a quality stock:
EBITDA (ttm)6: -4.79M
Net Income Avl to Common (ttm): -2.23M
Diluted EPS (ttm): -0.35
Return on Assets (ttm): -12.77%
Return on Equity (ttm): -12.54%
Profit Margin (ttm): -6.48%
Operating Margin (ttm): -15.07%
Enterprise Value/EBITDA (ttm)6: -2.73
lot of negative numbers there.
If they need a 2nd revenue stream, they should have picked one a little less crowded. Too many competitors, and too low a bar to entry.
Thats ok, with eight companies scrambling, I'm sure its covered. TKMR may even get a sliver of the Ebola pie until Glaxo gets ramped up.
Tenga mucho cuidado si usted está invirtiendo debido al brote de Ébola. Hay por lo menos ocho empresas que compiten con los tratamientos o curas. No hay ninguna razón para pensar que los brotes de Ebola se sumará mucho al resultado final de TKMR.
and for our English speaking friends:
Be very cautious if you're investing due to the Ebola outbreak. There are at least eight companies competing with treatments or cures. There is no reason to think Ebola outbreaks will add much to TKMR's bottom line.
Yep, guess you can only keep hoping it spreads so you can pump a stock.
Always says "At this time GPRO is not available for shorting."
Not that there arent any shares available. Scottrade previously allowed GPRO shorting, what changed?
What brokers are better for an occasional shorting? I think GPRO is getting a little pricy now.
Del Vecchio says Guerra departure was due to succession plans:
Luxottica (NYSE:LUX) founder Leonardo Del Vecchio decided to replace CEO Andrea Guerra following Guerra's rejection of his plans to take a more active role in the company and prepare it for his children."When approaching 80, one must think about one's children: you can put in writing that succession plans had a determining role in the decision," says Del Vecchio.
Note: This is not a good thing, CEO Andrea Guerra had done a good job for 10 years! Who knows whats going on in an old mans head, but the board shouldnt be a rubber stamp. .... and they paid 20 million euro to kick Guerra out?
Stock down only slighly, but long term, where does this leave us?